Cinclus Pharma
19.898
SEK
+0.16 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+0.16%
-23.4%
-34.97%
-
-
-
-
-
-38.97%
cincluspharma.com/sv
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CINPHA
Daily low / high price
19.116 / 20.27
SEK
Market cap
926.01M SEK
Turnover
1.02M SEK
Volume
51K
Latest videos
Financial calendar
Annual report
2025-02-20
Interim report
2025-05-19
General meeting
2025-05-22
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Trill Impact Ventures Pharma 1 | 8.0 % | 8.0 % |
Fjärde AP-fonden | 7.9 % | 7.9 % |
Futur Pension | 6.4 % | 6.4 % |
Linc AB | 5.0 % | 5.0 % |
Peter Unge | 4.4 % | 4.4 % |
Kjell Andersson | 4.1 % | 4.1 % |
Mikael Dahlströms Dödsbo | 4.0 % | 4.0 % |
Movestic Life Insurance AB | 3.8 % | 3.8 % |
Lennart Hansson through company | 2.3 % | 2.3 % |
Irrus Investments | 2.1 % | 2.1 % |
ShowingAll content types
Cinclus Pharma tillkännager överenskommelse gällande pediatrisk studieplan med FDA
Cinclus Pharma agrees on pediatric study plan with FDA
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools